- Home
- MSB vs RGNX Comparison
MSB vs RGNX Comparison
Compare MSB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- RGNX
- Stock Information
- Founded
- MSB 1961
- RGNX 2008
- Country
- MSB United States
- RGNX United States
- Employees
- MSB N/A
- RGNX N/A
- Industry
- MSB Metal Mining
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MSB Basic Materials
- RGNX Health Care
- Exchange
- MSB Nasdaq
- RGNX Nasdaq
- Market Cap
- MSB 351.7M
- RGNX 387.0M
- IPO Year
- MSB N/A
- RGNX 2015
- Fundamental
- Price
- MSB $26.82
- RGNX $7.05
- Analyst Decision
- MSB
- RGNX Strong Buy
- Analyst Count
- MSB 0
- RGNX 9
- Target Price
- MSB N/A
- RGNX $32.89
- AVG Volume (30 Days)
- MSB 35.3K
- RGNX 976.0K
- Earning Date
- MSB 01-01-0001
- RGNX 05-07-2025
- Dividend Yield
- MSB 25.73%
- RGNX N/A
- EPS Growth
- MSB 714.88
- RGNX N/A
- EPS
- MSB 7.00
- RGNX N/A
- Revenue
- MSB $26,785,162.00
- RGNX $83,328,000.00
- Revenue This Year
- MSB N/A
- RGNX $285.14
- Revenue Next Year
- MSB N/A
- RGNX N/A
- P/E Ratio
- MSB $3.91
- RGNX N/A
- Revenue Growth
- MSB 85.21
- RGNX N/A
- 52 Week Low
- MSB $15.93
- RGNX $5.62
- 52 Week High
- MSB $37.00
- RGNX $20.77
- Technical
- Relative Strength Index (RSI)
- MSB 48.77
- RGNX 45.61
- Support Level
- MSB $26.02
- RGNX $7.96
- Resistance Level
- MSB $27.77
- RGNX $8.35
- Average True Range (ATR)
- MSB 1.19
- RGNX 0.66
- MACD
- MSB 0.04
- RGNX -0.08
- Stochastic Oscillator
- MSB 41.96
- RGNX 22.99
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of the assets held. The company's principally wholly-owned segment is the iron ore mining segment and it generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.